Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis

Journal of Cardiac Failure

Volumn 10, Issue 6, 2004, Pages 452-459

  Ghali, Jalal K ^a   Dunselman, Peter ^b   Waagstein, Finn ^c   Goldstein, Sidney ^d   Gottlieb, Stephen S ^e   Deedwania, Prakash C ^f   Wikstrand, John C ^g,h  

^a Cardiac Centers of Louisiana   (United States)

^b Ignatius Hospital   (Netherlands)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

dose; Heart failure; medications

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIGITOXIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; METOPROLOL; PLACEBO; DIGITALIS GLYCOSIDE; DRUG DERIVATIVE; METOPROLOL SUCCINATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG RELEASE; DYSPNEA; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RR INTERVAL; CONGESTIVE HEART FAILURE; DELAYED RELEASE FORMULATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; ANALYTIC METHOD; DRUG DOSE REGIMEN; DRUG EFFECT; OUTCOMES RESEARCH; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DELAYED-ACTION PREPARATIONS; DIGITALIS GLYCOSIDES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS;

EID: 10344256131     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2004.02.008     Document Type: Article

References (26)

1. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldmanmd A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 104:2001;2996-3007
2. Holmer S.R., Kaissling B., Putnik K., Pfeifer M., Kramer B.K., Riegger G.A., et al. Beta-adrenergic stimulation of renin expression in vivo. J Hypertens. 15:1997;1471-1479
3. van Veldhuisen D.J. Low-dose digoxin in patients with heart failure: less toxic and at least as effective? Editorial comment. J Am Coll Cardiol. 39:2002;954-956
4. Rathore S.S., Curtis J.P., Wang Y., Bristow M.R., Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 289:2003;871-878
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 353:1999;2001-2007
6. Hjalmarson A., Goldstein S., Fagerberg B., Edel H., Waagstein F., Kjekhus J., Wikstrand J., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metroprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT HF). JAMA. 283:2000;1295-1302
7. Wikstrand J. MERIT-HF - description of the trial. Basic Res Cardiol. 95:(Suppl 1):2000;I/90-I/97
8. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 100:1999;2312-2318
9. The Network Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 19:1998;481-489
10. Nanas J.N., Alexopoulos G., Anastasiou-Nana M.I., Karidis K., Tirologos A., Zobolos S., et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol. 36:2000;2090-2095
11. Brunner-La Rocca H.P., Weilenmann K., Kiowski W., Maly F.E., Candinas R., Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormonal levels in patients with chronic heart failure. Am Heart J. 138:1999;654-662
12. van Veldhuisen D.J., Genth-Zotz S., Brouwer J., Boomsma F., Netzer T., Man In 'T Veld A.J., et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 32:1998;1811-1818
13. Pacher R., Stanek B., Globits S., Berger R., Hulsmann M., Wutte M., et al. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J. 17:1996;1223-1232
14. Tang W.H.W., Vagelos R.H., Yee Y.-G., Benedict C.R., Wilson K., Liss C.L., et al. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 39:2002;70-78
15. Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S., et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 12:1999;451-459
16. Holmer S.R., Hense H.-W., Danser A.H.J., Mayer B., Riegger G.A., Schunkert H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart. 80:1998;45-48
17. Teisman A.C.H., van Veldhuisen D.J., Boomsma F., de Kam P.J., Tjeerdsma G., Pinto Y.M., et al. Chronic beta-blocker treatment in patients with advanced heart failure: effects on neurohormones. Int J Cardiol. 73:2000;7-12
18. Fung J.W., Yu C.M., Yip G., Chan S., Yandle T.G., Richards A.M., et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 92:2003;406-410
19. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation. 101:2000;378-384
20. Campbell D.J., Aggarwal A., Esler M., Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 358:2001;1609-1610
21. McMurray J.J., Östergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 362:2003;767-771
22. Mohacsi P., Krum H., Rouleau J.L., Fowler M.B., Katus H.A., Coats A.J., et al. Does the degree of interference with the renin-angiotensin system influence the response to β-blockade in chronic heart failure? Results of the COPERNICUS Study. J Am Coll Cardiol. 39:5:(Suppl A):2002;167A
23. Carson P., Krum H., Cohn J.N., on behalf of the Val-HeFT Investigators. The effect of baseline ACE inhibitor dose on the efficacy of valsartan in Val-HeFT. Circulation. 106:19:(Suppl):2002;2522
24. Mancini D.M., Benotti J.R., Elkayam U., et al., for the PROMISE investigators and coordinators. Antiarrhythmic drug use and high serum levels of digoxin are independent adverse prognostic factors in patients with chronic heart failure. [abstract] Circulation. 84:(Suppl II):1991;II-243
25. Wikstrand J., Hjalmarson Å., Waagstein F., Fagerberg B., Goldstein S., Kjekshus J., et al., for the MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. Analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 40:2002;491-498
26. Gottlieb S.S., Fisher M.L., Kjekshus J., Deedwania P., Gullestad L., Vitovec J., et al., on behalf of the MERIT-HF Investigators. Tolerability of β-blocker initiation and titration in the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Circulation. 105:2002;1182-1188